Overview
c-ANCA (cytoplasmic anti-neutrophil cytoplasmic antibody) refers to IgG-class autoantibodies directed primarily against proteinase-3 (PR3), an enzyme found in neutrophils and monocytes. These autoantibodies play a significant role in autoimmune vasculitis by triggering excessive neutrophil activation, leading to vascular inflammation, vessel wall damage, and necrosis.
c-ANCA is a highly specific diagnostic marker for Granulomatosis with Polyangiitis (GPA), formerly known as Wegener’s granulomatosis. Less than 2% of c-ANCA–positive results occur in patients without this disease, making it a strong indicator of GPA.
ANCA-associated vasculitides (AAV) are a group of rare autoimmune disorders of unknown cause, characterized by inflammatory infiltration of blood vessels. Both p-ANCA and c-ANCA fall under this umbrella, with c-ANCA targeting PR3 and p-ANCA targeting myeloperoxidase (MPO). Detection of these antibodies helps identify the type of autoimmune vasculitis present. The c-ANCA test is performed on blood samples and is used for diagnosis as well as disease monitoring. c-ANCA
Symptoms
Symptoms associated with c-ANCA positivity arise from autoimmune vasculitis and depend on the organs involved. General symptoms commonly include fatigue, fever, generalized body aches, loss of appetite, and unexplained weight loss.
Organ-specific manifestations may involve the upper respiratory tract, lungs, kidneys, and blood vessels. Patients with Granulomatosis with Polyangiitis often present with ENT involvement, pulmonary symptoms, and renal abnormalities. The inflammatory process leads to narrowing and damage of blood vessels, which contributes to systemic and organ-related symptoms.
Causes
The presence of c-ANCA is caused by an autoimmune response in which the immune system produces antibodies against proteinase-3 within neutrophils. This abnormal immune activity results in neutrophil activation, endothelial injury, and inflammation of blood vessels.
c-ANCA is most strongly associated with Granulomatosis with Polyangiitis. It may also be variably present in other ANCA-associated vasculitides, though p-ANCA is more common in conditions such as microscopic polyangiitis, eosinophilic granulomatosis with polyangiitis, and inflammatory bowel disease. Drug-induced vasculitis and renal-limited vasculitis may occasionally show c-ANCA positivity.
Risk Factors
Risk factors for c-ANCA–associated diseases include the presence of autoimmune disorders and conditions that predispose individuals to immune dysregulation. Patients with a clinical suspicion of vasculitis involving the respiratory tract, kidneys, or systemic vasculature are at higher risk of testing positive.
Certain medications can contribute to drug-induced vasculitis with possible ANCA positivity. Although infections and other autoimmune conditions may lead to false-positive results, c-ANCA remains highly specific for GPA. Interpretation of results must consider clinical presentation, antibody titers, and associated laboratory findings.
Prevention
There is no direct method to prevent c-ANCA formation, as it is related to autoimmune disease mechanisms. However, early detection through appropriate testing plays a crucial role in preventing disease progression and organ damage.
Timely diagnosis allows for early initiation of treatment and ongoing monitoring of disease activity. Regular follow-up testing helps assess treatment response and detect relapses. Since test results alone are not diagnostic, they should always be interpreted alongside clinical findings and other investigations to ensure accurate diagnosis and management. Awareness of test limitations and potential false positivity due to infections or other autoimmune conditions is essential for appropriate clinical decision-making.
